HOMA-S is associated with greater HbAreduction with a GLP-1 analogue in patients with type 2 diabetes

Introduction: Exenatide, a glucagon-like peptide-1 (GLP-1) analogue, is an effective glucoregulator for treating overweight individuals, not at target HbAThis prospective study aimed to determine whether estimates of beta cell function (HOMA-B) and insulin sensitivity (HOMA-S) predict response to Exenatide treatment. Methods: Prospective data on 43 type 2 diabetes patients were collected for up to 2.8 years in UK primary care. HOMA-B and HOMA-S were estimated prior to initiating Exenatide, with monitoring of cardio-metabolic risk factors. Results: Mean (SD) age and BMI pre-treatment were 54.1±10.5 years and 35.7±7.5 kg/m 2 respectively. HbAdecreased (mean reduction 0.9%, p=0.04; p for trend=0.01) in 61% of patients. In univariate analyses, HOMA-S as a measure of insulin sensitivity was inversely (β= 0.41, p 0.009) related to change in HbA with no relation for HOMA-B. In a random effects regression model that included age at baseline, weight, LDL-C, HDL-C and triglycerides, change in HbA(β= 0.14, p